StockWatch
·
HomeLiveWeekly
Pharmaceutical Preparations
PatentAug 12, 2026, 07:32 AM

CTT Pharma Receives US Patent for Micelle Delivery Tech

AI Summary

CTT Pharmaceutical Holdings, Inc. announced it received a continuation-in-part (CIP) patent approval from the U.S. Patent Office for its micelle delivery technology. The patent, effective August 11, 2026, specifically covers nicotine, vitamins, and caffeine. This approval allows the company's technology to be utilized in various dissolvable forms, including strips, gum, pouches, lozenges, and dissolving tablets, enhancing its intellectual property portfolio.

Key Highlights

  • CTT Pharma received a continuation-in-part (CIP) patent approval from the U.S. Patent Office.
  • The patent became effective on August 11, 2026.
  • It specifically covers nicotine, vitamins, and caffeine using the company's micelle delivery technology.
  • The technology can be used for dissolvable strips, gum, pouches, lozenges, and dissolving tablets.
  • The company plans to continue strengthening its patent portfolio.
View SEC Filing
CTTH
Pharmaceutical Preparations
CTT PHARMACEUTICAL HOLDINGS, INC.

Price Impact

More from CTTH

InvestmentJul 13, 4:32 PM

CTT Pharma Registers 6.25M Shares for ELOC

Corporate ActionJun 29, 10:41 AM

CTT PHARMACEUTICAL Holdings Registers 6.25M Shares for Resale via ELOC

Loan & DebtJun 16, 4:17 PM

CTT Pharma May Raise Up To $10M Via Equity Line of Credit

More in Patent

ATHE1d ago, 6:12 AM

Alterity Therapeutics Granted New U.S. Patent for ATH434

SPRC2d ago, 9:07 AM

SciSparc Subsidiary NeuroThera Labs Gets Japanese Patent

SPRC2d ago, 8:26 AM

SciSparc Subsidiary NeuroThera Granted Japanese Patent for Drug Combination